

**Joint Psychopharmacologic Drugs Advisory Committee (PDAC) and
Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting
October 9, 2020
Pre-recorded Presentations**

Both the Food and Drug Administration (FDA) and Alkermes Inc. have prepared pre-recorded presentations for the October 9, 2020, joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. These pre-recorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day.**

The recordings of the presentations can be found at the following addresses:

FDA Presentations (listed in viewing order):

1. ALKS 3831 for Schizophrenia: Clinical Overview of Efficacy and Safety by Cathy Southammakosane, MD: <https://collaboration.fda.gov/pjlyt8xkeass/>
2. Consideration of Potential Risks Associated with ALKS 3831 in Real World Settings of Opioid Use by Celeste Mallama, PhD, MPH: <https://collaboration.fda.gov/pe85foili45z/>

Alkermes Inc. Presentation:

1. Olanzapine/Samidorphane (OLZ/SAM) NDA 213, 378 by Alkermes, Inc: <https://collaboration.fda.gov/pc3h78zmardl/>

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at: <https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-time-agenda-and-meeting-materials-october-9-2020-joint-meeting-psychopharmacologic-drugs>